It rose to fame after it was approved based on a small study showing it appeared to help symptoms of patients reporting to the hospital with acute heart failure symptoms.

FORBES: AHA 2010

Some explicit criticism also came from Wall Street, where analysts were quick to dismiss the study for several reasons, including flaws such as a failure to evaluate the potential impact of label changes on reporting.

FORBES: The Confusion Over A Pair Of Diabetes Drugs And Pancreatitis

Given the failure of Study 377 to demonstrate efficacy, it was rightly concluded that a submission for new wording on safety should not be made.

BBC: GlaxoSmithKline logo